|
|
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).
Number of employees : 43 people.
|
|
|
| 2020 | 2021 | Delta | | Immuno-oncology | 1.18 | 100% | - | - | - |
| USD in Million |
|
|
|
| 2020 | 2021 | Delta | | United States and Ireland | 1.18 | 100% | - | - | - |
| USD in Million |
|
|
|
| Vote  | Quantity | Free-Float | Company-owned shares | Total Float |
| Stock A |
1 |
40,747,065 |
25,623,767 |
62.9% |
0 |
0.0% |
62.9% |
|
|
|
| Name | Equities | % | | venBio Partners LLC | 9,699,925 |
23.8% | | LSV CAPITAL MANAGEMENT LLC | 4,926,963 |
12.1% | | Vivo Capital LLC | 4,220,048 |
10.4% | | Fidelity Management & Research Co. LLC | 3,985,922 |
9.80% | | Logos Global Management LP | 3,011,352 |
7.40% | | SSgA Funds Management, Inc. | 2,133,744 |
5.25% | | The Vanguard Group, Inc. | 1,302,215 |
3.20% | | Wellington Management Co. LLP | 1,128,101 |
2.77% | | Janus Henderson Investors US LLC | 918,908 |
2.26% | | Redmile Group LLC | 772,397 |
1.90% |
|
|
|
Sector Bio Therapeutic Drugs
| | 1st jan. | Capi. (M$) |
 | ALX ONCOLOGY HOLDINGS INC. | -32.43% | 592 |
| | | |
| GILEAD SCIENCES, INC. | -13.29% | 78 912 |
| VERTEX PHARMACEUTICALS | 34.12% | 75 532 |
| REGENERON PHARMACEUTICALS, INC. | -0.45% | 67 214 |
 | WUXI APPTEC CO., LTD. | -20.10% | 40 830 |
| BIONTECH SE | -37.80% | 38 968 |
 | GENMAB A/S | 0.23% | 23 726 |
 | ARGENX SE | 16.11% | 20 669 |
| BEIGENE, LTD. | -28.41% | 20 070 |
| NEUROCRINE BIOSCIENCES, INC. | 24.02% | 10 102 |
| SAREPTA THERAPEUTICS, INC. | 21.04% | 9 545 |
| KARUNA THERAPEUTICS, INC. | 111.77% | 9 277 |
| LEGEND BIOTECH CORPORATION | 0.79% | 7 652 |
| EXELIXIS, INC. | 6.56% | 6 248 |
| ASCENDIS PHARMA A/S | -18.06% | 6 152 |
| HALOZYME THERAPEUTICS, INC. | 7.29% | 5 944 |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | 7.53% | 5 177 |
 | PHARMAESSENTIA CORPORATION | 83.28% | 5 091 |
| INTRA-CELLULAR THERAPIES, INC. | 2.35% | 5 057 |
| ARROWHEAD PHARMACEUTICALS, INC. | -28.67% | 5 006 |
| MIRATI THERAPEUTICS, INC. | -41.12% | 4 803 |
Connections : ALX Oncology Holdings Inc. |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
